about
A Randomized Trial of Lorcaserin and Lifestyle Counseling for Maintaining Weight Loss Achieved with a Low-Calorie Diet.Reconsidering the Psychosocial-Behavioral Evaluation Required Prior to Bariatric Surgery.Short- and Long-Term Changes in Health-Related Quality of Life with Weight Loss: Results from a Randomized Controlled Trial.Combined Treatment for Obesity and Depression: A Pilot StudyAlcohol Intake and Weight Loss During Intensive Lifestyle Intervention for Adults with Overweight or Obesity and Diabetes.Weight Stigma Affects Men TooLiraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled TrialSymptom prevalence differences of depression as measured by BDI and PHQ scales in the Look AHEAD studyA Protocol to Deliver Intensive Behavioral Therapy (IBT) for Obesity in Primary Care Settings: The MODEL-IBT ProgramTwo-Year Results of Think Health! ¡Vive Saludable!: A Primary Care Weight-Management TrialEffects of Liraglutide and Behavioral Weight Loss on Food Cravings, Eating Behaviors, and Eating Disorder PsychopathologyImpact of Intensive Lifestyle Intervention on Neural Food Cue Reactivity: Action for Health in Diabetes Brain Ancillary StudyHistory of Cardiovascular Disease, Intensive Lifestyle Intervention, and Cardiovascular Outcomes in the Look AHEAD TrialEnd-of-Trial Health Outcomes in Look AHEAD Participants who Elected to have Bariatric SurgeryWeight bias internalization in a commercial weight management sample: prevalence and correlatesIntensive Behavioral Therapy for Obesity Combined with Liraglutide 3.0 mg: A Randomized Controlled TrialWeight Change 2 Years After Termination of the Intensive Lifestyle Intervention in the Look AHEAD Study
P50
Q47172695-7DE935B2-5C32-4F35-8EF4-6EFDA2A6FA5FQ48338822-8FD13ED5-F858-416A-A420-FDE205352E5BQ53405967-C74858D4-2705-4848-A896-EC31DDEDDC3AQ63457075-C4E885F2-1228-42DF-B219-4F15DFEEC5A8Q64933835-BCDFB313-7EC3-4640-BD00-FDD94BBB55E4Q88554032-414378B5-E054-4101-8326-86342B2533D2Q89851700-879BBCA6-D302-4D93-AD69-948CD2B010EBQ90015436-DA5F0DB7-B761-48CC-8EC4-E2127D1F1CD2Q90208791-4768DBF3-CB49-4FCA-8C2A-E339D19EA5F8Q91218099-CDCD56D6-2FF3-4A5E-BD76-A9376B9496E1Q91352100-8CC21962-FAD5-477E-82F5-F63EED602BF7Q92187143-4961E67D-4389-4D5A-8EF8-076E832FDA02Q92395399-706CBB71-F661-44E5-BF36-6A9AB7723072Q92547147-4D12D054-3F56-48F4-BCD6-5DE0A193555DQ92891101-76D8E71F-4A7C-4AC2-9D4B-E671C3B122EFQ93027238-DA61875D-9B43-4ECF-937F-EC53E6AAAE3EQ93148597-BDE376D9-284E-4059-AF38-F8623AB2C0A6
P50
description
researcher
@en
wetenschapper
@nl
name
Thomas A Wadden
@en
Thomas A Wadden
@nl
type
label
Thomas A Wadden
@en
Thomas A Wadden
@nl
prefLabel
Thomas A Wadden
@en
Thomas A Wadden
@nl
P31
P496
0000-0002-0438-4609